BACKGROUND: Familial amyloid polyneuropathies (FAP) patients manifest progressive sensory-motor length dependent polyneuropathy and severe autonomic dysfunction. In this setting the autonomic manifestations include mainly postural hypotension, nausea and vomiting, diarrhea and constipation, sphincter distur- bances and erectile dysfunction. Reproducible quantitative evaluation of signs and symptoms are necessary for the assessment of treatment efficacy. OBJECTIVE: To determine the reliability of a new compound test cumulating evaluation of autonomic and sensorymotor dysfunction in FAP. METHODS: Compound Autonomic Dysfunction Test (CADT) is a new questionnaire to evaluate the main symptoms of autonomic dysfunction observed in FAP. A separate functional questionnaire assesses the disability due to the sensorymotor deficit (Modified Norris Test; MNT). The compound test takes approximately 10 minutes to perform. In this prospective study, we enrolled consecutively 60 FAP patients to test interexaminer reliability, i.e., both questionnaires rated independently by 2 examiners. We also evaluate the reliability of testing patients face to face and by phone call, by the same examiner. RESULTS: Interexaminer reliabilities tested were high (ICC=0.92 for the CADT, p < 0.001; and ICC = 0.99 for the MNT, p < 0.001). In addition, testing by phone as compared to testing during the initial medical visit by the same investigator gave similar results (ICC = 0.91 for the CADT, p < 0.001; and ICC = 0.98 for the MNT, p < 0.001). CONCLUSION: In FAP, the CADT and the MNT have good reliability inter-investigators as well as between face to face and by phone call, by the same examiner. This newly designed compound test is a simple and reproducible scale which is adapted to evaluate the main neuropathic manifestations and will be useful for assessment of future treatments in this condition.
BACKGROUND:Familial amyloid polyneuropathies (FAP) patients manifest progressive sensory-motor length dependent polyneuropathy and severe autonomic dysfunction. In this setting the autonomic manifestations include mainly postural hypotension, nausea and vomiting, diarrhea and constipation, sphincter distur- bances and erectile dysfunction. Reproducible quantitative evaluation of signs and symptoms are necessary for the assessment of treatment efficacy. OBJECTIVE: To determine the reliability of a new compound test cumulating evaluation of autonomic and sensorymotor dysfunction in FAP. METHODS: Compound Autonomic Dysfunction Test (CADT) is a new questionnaire to evaluate the main symptoms of autonomic dysfunction observed in FAP. A separate functional questionnaire assesses the disability due to the sensorymotor deficit (Modified Norris Test; MNT). The compound test takes approximately 10 minutes to perform. In this prospective study, we enrolled consecutively 60 FAPpatients to test interexaminer reliability, i.e., both questionnaires rated independently by 2 examiners. We also evaluate the reliability of testing patients face to face and by phone call, by the same examiner. RESULTS: Interexaminer reliabilities tested were high (ICC=0.92 for the CADT, p < 0.001; and ICC = 0.99 for the MNT, p < 0.001). In addition, testing by phone as compared to testing during the initial medical visit by the same investigator gave similar results (ICC = 0.91 for the CADT, p < 0.001; and ICC = 0.98 for the MNT, p < 0.001). CONCLUSION: In FAP, the CADT and the MNT have good reliability inter-investigators as well as between face to face and by phone call, by the same examiner. This newly designed compound test is a simple and reproducible scale which is adapted to evaluate the main neuropathic manifestations and will be useful for assessment of future treatments in this condition.
Authors: K Tashima; Y Ando; H Terazaki; S Yoshimatsu; O B Suhr; K Obayashi; T Yamashita; E Ando; M Uchino; M Ando Journal: J Neurol Sci Date: 1999-12-01 Impact factor: 3.181
Authors: M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: D Adams; D Samuel; C Goulon-Goeau; M Nakazato; P M Costa; C Feray; V Planté; B Ducot; P Ichai; C Lacroix; S Metral; H Bismuth; G Said Journal: Brain Date: 2000-07 Impact factor: 13.501
Authors: I S J Merkies; P I M Schmitz; F G A van der Meché; J P A Samijn; P A van Doorn Journal: J Neurol Neurosurg Psychiatry Date: 2002-05 Impact factor: 10.154
Authors: Vincent Algalarrondo; Eve Piekarski; Ludivine Eliahou; Dominique Le Guludec; Michel S Slama; François Rouzet Journal: Curr Cardiol Rep Date: 2018-03-24 Impact factor: 2.931
Authors: David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini Journal: J Neurol Date: 2020-01-06 Impact factor: 4.849
Authors: Louise-Laure Mariani; Pierre Lozeron; Marie Théaudin; Zoia Mincheva; Aissatou Signate; Beatrice Ducot; Vincent Algalarrondo; Christian Denier; Clovis Adam; Guillaume Nicolas; Didier Samuel; Michel S Slama; Catherine Lacroix; Micheline Misrahi; David Adams Journal: Ann Neurol Date: 2015-10-07 Impact factor: 10.422